针对免疫性血小板缺血的临床方法的建议:西班牙ITP工作组 (GEPTI)
María Eva Mingot-Castellano1, Mariana Canaro Hirnyk2, Blanca Sánchez-González3
1Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla, 41013 Sevilla, Spain.
Journal of clinical medicine
|October 28, 2023
概括
这项研究更新了管理原发性免疫血小板缺血症 (ITP) 的临床指南,这是一种影响血小板水平的复杂自身免疫性疾病. 修订后的建议旨在改善ITP患者的诊断和治疗策略.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 初级免疫性血小板缺血 (ITP) 是一种自身免疫性疾病,其特征是免疫失调导致血小板破坏增加和血小板生产减少.
- 不同的呈现和ITP的临床进展使个性化诊断和管理策略变得复杂.
- 西班牙ITP集团 (GEPTI) 的现有指南于2021年更新,成为西班牙的关键参考.
研究的目的:
- 为初级ITP的综合管理提供一个最新的,实用的工具.
- 纳入ITP诊断和治疗策略的最新进展.
- 改进对初级ITP的诊断和管理的建议.
主要方法:
- 对初级ITP的现有共识指南的审查和更新.
- 纳入新的诊断工具和治疗策略.
- 为完整的ITP管理制定实际建议.
主要成果:
- 对初级ITP的诊断和管理的修订指南.
- 包括有关ITP病原和临床过程的最新信息.
- 实用建议,以促进个性化患者护理.
结论:
- 更新的指导方针为管理初级ITP提供了实际框架.
- 由于ITP研究的不断发展,对指南的持续审查和调整至关重要.
- 这些建议旨在优化患者在原发性免疫性血栓塞缩症的治疗结果.
相关概念视频
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
10
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
10
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
537
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
537
Blood Transfusion and Agglutination
10.8K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.8K
Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
192
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
192


